Related Experiment Video
Updated: Mar 12, 2026

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer
Published on: April 21, 2022
Mucopolysaccharidosis VI: pathophysiology, diagnosis and treatment
1UCSF Benioff Children's Hospital Oakland, 747 52nd St., Oakland, CA 94609, United States of America, pharmatz@mail.cho.org.
Abstract:
Mucopolysaccharidosis VI (MPS VI), or Maroteaux-Lamy syndrome, is an autosomal recessive lysosomal storage disorder caused by deficient activity of the enzyme arylsulfatase B (ASB). Progressive accumulation of glycosaminoglycans (GAGs) in organs and tissues leads to the development of multisystem clinical manifestations. The presentation of MPS VI is genotypically and phenotypically diverse, with a large number of potential disease-causing mutations and a phenotypic spectrum ranging from very slowly to very rapidly progressing disease. Diagnosis of MPS VI relies on presence of clinical features, increased GAG levels in urine or low ASB activity in dried blood spots, and measurement of enzyme activity levels in leukocytes or fibroblasts. The management of MPS VI involves enzyme replacement therapy and medical and surgical treatment of disease manifestations. Liquid chromatography/tandem mass spectrometry of GAG-derived disaccharides in blood or urine is emerging as a valuable method in the diagnosis, prognosis and assessment of therapeutic efficacy in MPS VI.
Insights
Mucopolysaccharidosis VI (MPS VI) is a rare genetic disorder due to arylsulfatase B deficiency. New mass spectrometry methods show promise for diagnosing MPS VI, assessing its progression, and monitoring treatment effectiveness.
Area of Science:
- Biochemistry
- Genetics
- Rare Diseases
Background:
- Mucopolysaccharidosis VI (MPS VI), or Maroteaux-Lamy syndrome, is an autosomal recessive lysosomal storage disorder.
- It results from deficient arylsulfatase B (ASB) activity, leading to progressive glycosaminoglycan (GAG) accumulation.
- MPS VI exhibits significant genotypic and phenotypic diversity, impacting disease progression.
Purpose of the Study:
- To highlight the diagnostic challenges and emerging methods for Mucopolysaccharidosis VI.
- To discuss the current management strategies for MPS VI.
- To emphasize the role of advanced analytical techniques in MPS VI care.
Main Methods:
- Diagnosis relies on clinical evaluation, elevated urinary GAGs, low ASB activity in blood spots, and enzyme assays in leukocytes or fibroblasts.
- Liquid chromatography/tandem mass spectrometry (LC-MS/MS) is utilized for analyzing GAG-derived disaccharides.
- Assessment includes blood or urine sample analysis.
Main Results:
- Traditional diagnostic methods include clinical signs, biochemical markers, and enzyme activity tests.
- LC-MS/MS analysis of GAG-derived disaccharides in biological samples is emerging as a key technique.
- This method offers potential for improved diagnosis, prognosis, and therapeutic monitoring in MPS VI.
Conclusions:
- MPS VI diagnosis requires a combination of clinical and biochemical assessments.
- Enzyme replacement therapy and symptomatic treatments are current management approaches.
- Advanced mass spectrometry techniques are poised to enhance the clinical management of MPS VI.
Related Concept Videos
Lysosomal Hydrolases
Proteoglycans
Glycosaminoglycans
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Inborn Errors of Metabolism
Biosynthesis of Polysaccharides

